Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-820132 in Subjects With Type 2 Diabetes Treated With Metformin Monotherapy.
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2012
At a glance
- Drugs BMS 820132 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Biomarker
- 26 Mar 2012 Actual end date changed from Oct 2011 to Nov 2011 as reported by ClinicalTrials.gov.
- 29 Feb 2012 Actual patient number changed from 64 to 67 as reported by ClinicalTrials.gov.
- 29 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.